Characteristics and hematologic response of AML patients treated by RAPA
. | . | . | . | . | . | FLT3 . | . | . | |
|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y . | FAB . | WBC count, cells × 109/L . | Disease status . | Cytogenetics . | ITD . | D835 . | Response to RAPA, d28* . | |
| 14 | 55 | 0 | 2.5 | Rel | 46 XY del5 | - | ND | PR | |
| 18 | 59 | 4 | 103 | Rel | 46 XX | - | ND | PR | |
| 39 | 73 | 2 | 20.3 | Refr | 46XY, +8 | - | - | PR | |
| 43 | 74 | 4 | 3.6 | Rel | 46XX | + | - | PD | |
| 22 | 67 | t-AML | 25 | Diag | 46 XY | - | - | PR | |
| 8 | 75 | 5 | 55.2 | Refr | 46 XX | - | - | PD | |
| 31 | 72 | 2 | 1.8 | Refr | 46 XX,t (16;21) | ND | ND | PD | |
| 20 | 56 | 1 | 26.9 | Rel | Failure | + | - | SD | |
| 19 | 77 | 1 | 20.7 | Refr | 46 XX | - | ND | PD | |
. | . | . | . | . | . | FLT3 . | . | . | |
|---|---|---|---|---|---|---|---|---|---|
| Patient no. . | Age, y . | FAB . | WBC count, cells × 109/L . | Disease status . | Cytogenetics . | ITD . | D835 . | Response to RAPA, d28* . | |
| 14 | 55 | 0 | 2.5 | Rel | 46 XY del5 | - | ND | PR | |
| 18 | 59 | 4 | 103 | Rel | 46 XX | - | ND | PR | |
| 39 | 73 | 2 | 20.3 | Refr | 46XY, +8 | - | - | PR | |
| 43 | 74 | 4 | 3.6 | Rel | 46XX | + | - | PD | |
| 22 | 67 | t-AML | 25 | Diag | 46 XY | - | - | PR | |
| 8 | 75 | 5 | 55.2 | Refr | 46 XX | - | - | PD | |
| 31 | 72 | 2 | 1.8 | Refr | 46 XX,t (16;21) | ND | ND | PD | |
| 20 | 56 | 1 | 26.9 | Rel | Failure | + | - | SD | |
| 19 | 77 | 1 | 20.7 | Refr | 46 XX | - | ND | PD | |
WBC indicates white blood cells; Rel, relapse; ND, not done; PR, partial response; Refr, refractory; PD, progressive disease; t-AML, transformed-AML (AML secondary to refractory anemia with excess blasts); diag, diagnosis; and SD, stable disease.
There were 9 AML patients treated by RAPA alone (6 mg/dL then 2 mg/d), and response was monitored at day 28 in blood and marrow